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Abstract
Background: The reason for the insufficient catch-up growth 
seen in 10% of children born small for gestational age (SGA) 
is poorly understood. Disturbances in the growth hormone 
(GH) – insulin-like growth factor (IGF) axis might underlie this 
failure to show sufficient catch-up growth. Conclusion: This 
review summarizes insights gained in the molecular and 
(epi) genetic mechanisms of the GH-IGF axis in short children 
born SGA. The most notable anomalies of the IGF system are 
the lowered IGF-I levels in both cord blood and the placenta, 
and the increased expression of IGF-binding proteins 
(IGFBP)-1 and IGFBP-2, which inhibit IGF-I, in the placenta of 
SGA neonates. These observations suggest a decreased bio-
activity of IGF-I in utero. IGF-I levels remain reduced in SGA 
children with short stature, as well as IGFBP-3 and acid-labile 
subunit levels. Proteolysis of IGFBP-3 appears to be in-
creased. © 2019 The Author(s) 
Published by S. Karger AG, Basel
Introduction
Short stature is one of the most common medical con-
cerns in childhood. Small for gestational age (SGA) ac-
counts for approximately 20% of all cases of short stature 
[1]. SGA refers to the size of an infant at birth, and is de-
fined as a birth weight and/or birth length below the –2.0 
SDS for the gestational age [2]. In order to determine 
whether a child is born SGA, accurate information on 
gestational age, birth weight and birth length is required, 
as well as data derived from an appropriate reference pop-
ulation [2]. The term intrauterine growth retardation 
(IUGR) is often used synonymously with the term SGA. 
However, IUGR is a prenatal diagnosis and refers to a de-
celeration of fetal growth. IUGR does not always result in 
SGA birth, for example, a child with IUGR in late gesta-
tion may exhibit a normal size at birth. Similarly, being 
born SGA does not necessarily mean that IUGR occurred. 
Numerous factors are associated with SGA birth, such as 
maternal, placental, and demographic factors [3, 4]. How-
ever, in 40% of the children no underlying cause can be 
determined. Nevertheless, it is important to try and iden-
tify an underlying cause since this may have consequenc-
es for health prognosis and treatment.
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A majority of children born SGA show spontaneous 
catch-up growth during the first years of life. However, 
approximately 10% of all children born SGA fail to show 
sufficient catch-up growth, and will continue to have a 
short stature throughout childhood and adolescence [5, 
6]. Without growth hormone (GH) treatment, these chil-
dren will reach an adult height well below the normal 
range and/or their target height range [7]. The reason for 
this insufficient catch-up growth is poorly understood. It 
has been hypothesized that disturbances in the GH-insu-
lin-like growth factor (IGF) axis might underlie this fail-
ure to show sufficient catch-up growth [8–10].
Also, the genetic nature of short stature in SGA chil-
dren is still largely unknown despite adult height being 
one of the most heritable human traits [11]. A small num-
ber of genetic mutations (< 1%), mainly in genes coding 
for proteins that are involved in the GH-IGF axis, has 
been found in SGA children with short stature [12–15]. 
Furthermore, disturbances in epigenetics, such as DNA 
methylation, during critical periods of intrauterine devel-
opment are presumed to play a role [16, 17]. With ad-
vances in genetics, the list of genes and epigenetic defects 
involved is expected to grow [18].
For over 25 years, our research group and others have 
been investigating children with short stature who were 
born SGA. This review summarizes the latest insights 
gained in the molecular and (epi) genetic mechanisms of 
the GH-IGF axis in humans, with particular focus on 
short children born SGA. Also, the effects of GH treat-
ment are discussed.
GH and GH Receptor
The GH-axis plays a critical role in many physiological 
processes. It is very complex and is represented schemat-
ically in Figure 1 [19]. The pulsatile secretion of GH sets 
a cascade in motion involving multiple organs and sys-
tems [19, 20]. Also, the factors determining normal 
growth depend on a child’s age. For example, intrauterine 
growth is not dependent on GH since infants with con-
genital absence of the pituitary are born normal in size. 
Early postnatal growth up until 6 months of age is pre-
dominantly insulin dependent [19–21]. After these first 
6 months, GH becomes increasingly important in con-
trolling longitudinal growth. Several studies have demon-
strated that up to 60% of SGA children with insufficient 
catch-up growth show a reduction in physiological 24-h 
GH secretion and/or low GH peaks during provocation 
tests [9, 10]. The reason for this is unknown.
The effects of GH can be accomplished only in the 
presence of a normal functioning GH receptor (GHR). 
The GHR gene is located on chromosome 5, and there are 
2 isoforms in humans: a full-length isoform and an iso-
form that lacks exon 3 (d3-GHR). Polymorphisms of the 
d3-GHR gene are present in heterozygosis in ∼40% of the 
healthy population, and in homozygosis in ∼15%. It re-
sults in the loss of amino acid residues 7–28 and the ami-
no acid substitution A6D at the N-terminal part of the 
extracellular receptor domain [22]. In vitro, the d3-GHR 
polymorphism was found to enhance the signal transduc-
tion of the GHR in exposure to GH compared to the full-
length allele homodimer [23]. Several studies have shown 
an association between d3-GHR and increased growth 
response to GH treatment in children born SGA [22, 24]. 
However, results regarding the exon 3 GHR polymor-
phism and GH responsiveness are discordant.
Insulin-Like Growth Factors
Although some of the effects of GH are direct actions, 
most effects are mediated through the peptide hormone 
IGF-I [19, 25]. The IGF family includes IGF-I, IGF-II, 
3 membrane bound receptors, several IGF-binding pro-
teins (IGFBPs), and the acid-labile subunit (ALS). IGF-I 
and IGF-II are closely related, single chain polypeptides, 
which share approximately 50% of their amino-acid se-
quence [19]. IGF-I, but especially IGF-II, play a dominant 
role in early fetal development through binding to the 
IGF-I receptor [26–28]. However, after organogenesis, 
GH-dependent IGF-I bioactivity becomes more impor-
tant [29]. The role of IGF-II during postnatal life remains 
unclear. In mice, the disruption of the paternally inher-
ited IGF-II allele causes severe intrauterine growth re-
striction, whereas the disruption of the maternally inher-
ited IGF-II allele has no effect on growth [30]. Begemann 
et al. [31] reported an IGF-II variant with evidence of 
pathogenicity in a multigenerational family with severe 
intrauterine and postnatal growth restriction and a Sil-
ver-Russell syndrome phenotype. 
Tzschoppe et al. [32] compared the levels of IGF-I and 
IGF-II in umbilical cord blood between IUGR neonates, 
SGA neonates without IUGR and appropriate for gesta-
tional age (AGA) neonates. The concentrations of IGF-I 
and IGF-II in cord blood of IUGR neonates were reduced 
compared to those in both SGA and AGA neonates. In 
SGA neonates, IGF-I levels were also lower compared to 
AGA neonates although to a lesser extent, whereas IGF-II 
levels were similar. This might indicate that different 
mechanisms play a role in IUGR and SGA. The low levels 
of IGFs in IUGR neonates, as also reported by others, 
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might not only reflect a low birth weight per se, but could 
also be related to placental insufficiency [33, 34]. The del-
eterious fetal environment caused by placental insuffi-
ciency could induce lasting alterations in IGF signaling. 
In contrast, in SGA neonates, with a physiological intra-
uterine growth pattern and only moderately reduced 
IGF-I levels, other constitutionally derived factors are in-
volved in the regulation of the IGF system, such as epi-
genetic changes in growth-related genes [32, 34, 35]. For 
example, the GH-IGF-I axis can be affected by a different 
pattern of histone modifications of GH response ele-
ments and a changed epigenetic profile of the IGF-I gene 
[35]. Indeed, it has been found that the IGF1 gene pro-
moter is hypermethylated in the placenta of SGA neo-
nates when compared to AGA neonates, being associated 
with a lower level of IGF-I mRNA and protein in the SGA 
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Fig. 1. Schematic view of the main components of the GH-IGF 
axis. GH releasing hormone (GHRH) is secreted in a pulsatile 
manner by the hypothalamus and stimulates the secretion of GH 
by the somatotrophic cells of the anterior pituitary. Somatostatin 
inhibits the release of GH. In the circulation, GH can be found free 
or bound to GH binding protein (not shown). Mutations in genes 
encoding GHRH, GHRH receptor (not shown), somatostatin re-
ceptor (not shown), GH, and GHR usually do not result in SGA 
birth. GH activates the GHR on the liver and various other target 
tissues. This may either result in direct, metabolic effects GH or 
indirect actions being mediated trough IGF-I. IGF-I can act in 
mainly an autocrine, paracrine, or endocrine fashion through 
binding to the IGF-IR which is expressed by nearly all cell types. 
IGF-II, which can also bind to the IGF-IR and at least in vitro, has 
similar effects as IGF-I, is not directly under the influence of GH. 
The IGFs exert negative feedback on GHRH and GH secretion and 
positive feedback on somatostatin release. The IGFs in the circula-
tion are strongly bound to IGFBPs. This leaves a very small fraction 
of IGFs in the free unbound form. IGFBPs are important for the 
regulation of IGF bioavailability. Under normal circumstances 
IGFBP-3, mainly produced by the liver, is the most abundant 
IGFBP in the circulation. Together with an IGF and the ALS it 
forms a high molecular weight ternary complex that cannot pass 
the blood capillaries. ALS synthesis and release is GH-dependent. 
Most IGFBPs can also exert IGF-independent effects. At the tissue 
level, IGFs can be released from the IGFBPs by the action of vari-
ous IGFBP proteases. GH, growth hormone; GHRH, GH releasing 
hormone; GHR, GH receptor; IGF, insulin-like growth factor; 
IGF-IR, IGF-I receptor; IGFBP, IGF-binding proteins; ALS, acid-
labile subunit [96]. 
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group [17]. Also, Mas-Parés et al. [36] studied the mi-
croRNA profile in umbilical cord tissue of AGA and SGA 
subjects and found that several umbilical cord microR-
NAs may be associated with catch-up growth in SGA in-
fants.
Short children born SGA have on average low-normal 
serum IGF-I levels, which might be partly explained by a 
reduction in spontaneous GH secretion [9, 10, 37]. Also, 
several polymorphisms in the 5′ and 3′ regions of the 
 IGF-I gene have been associated with low serum IGF-I 
levels and the SGA phenotype [38, 39]. There are also a 
few case reports describing mutations in the IGF1 gene 
showing variable degrees of both pre- and postnatal 
growth failure, deafness, and mental retardation [40, 41].
IGF-I exerts its effects through binding to the IGF-I 
receptor. The IGF1R gene plays an important role in pre-
natal and postnatal growth. There are several case-reports 
describing IGF1R gene haplo insufficiency leading to se-
vere intrauterine and postnatal growth retardation, mi-
crocephaly and various other clinical manifestations, for 
example, feeding problems and delayed motor and men-
tal development, but the clinical picture is very heteroge-
neous [4, 41]. In a cohort of 100 short SGA children, 
2 heterozygous IGF1R deletions were found [13]. In vitro 
functional analysis showed similar levels of IGF1R auto 
phosphorylation, a tendency toward reduced total IGF1R 
protein expression, and reduced intracellular activation 
of protein kinase B compared with healthy controls. This 
suggests that IGF1R deletions are characterized by a low-
er number of IGF1 receptors on the cell surface, resulting 
in reduced signal transduction [13, 14].
IGF Binding Proteins
The majority of IGF-I is firmly bound to IGFBPs. 
IGFBPs play an important role in regulating the availabil-
ity of IGF-I. These binding proteins act as carrier proteins, 
transporting IGF-I from the circulation to the target tis-
sues and prolonging the half-life of IGF-I [19, 42]. Six 
IGFBPs have been identified, and they show similar orga-
nization, mostly at the NH2- and COOH-terminal do-
mains [43, 44]. All of the IGFBPs have a similar or higher 
binding affinity for IGF-I than for the IGF-I receptor. This 
suggests that the formation of IGF-I-IGFBP complexes 
competes with binding of IGF-I to the IGF-I receptor [45]. 
In healthy subjects, most of the serum  IGF-I circulates in 
a 150 kD ternary complex with IGFBP-3 (and to a much 
lesser extent IGFBP-5) and ALS [42, 46, 47]. Only 1–5% 
of IGF-I is unbound with a short half-life of 10–12 min. 
Figure 2 shows how proteases cleave the IGFBPs to release 
free IGF-I into the circulation [48]. 
To date, no mutations have been reported in IGFBP 
genes [49]. Animal IGFBP knockout studies demonstrat-
ed only minor effects on fetal and postnatal growth [50]. 
Studies in IGFBP transgenic mice revealed that the pre-
dominant effect of overexpression of the IGFBPs has been 
growth inhibition, as would be anticipated from inhibi-
tion of the actions of IGF-I and IGF-II [51, 52]. This has 
also been described in children with chronic renal insuf-
ficiency [53, 54]. 
IGFBPs also bind non-IGF ligands in the extracellular 
space, cell membrane, cytoplasm and nucleus, thereby 
modulating cell proliferation, survival and migration in 
an IGF-independent manner. In general, IGFBP activity 
is regulated by transcriptional mechanisms as well as by 
post-translational modifications and proteolysis [55, 56]. 
To our knowledge, only IGFBP-1, -2 and -3, ALS, and 
ternary complex formation have been studied specifically 
in short SGA children, and is discussed below. Since 
IGFBP-1 and -2 are mainly involved in metabolic signal-
ing rather than growth, these are discussed only briefly.
IGF Binding Protein-1
IGFBP-1, predominantly produced by the liver and 
kidney, is an acute regulator of IGF-I bioavailability and 
plays an important role in glucose metabolism and ho-
meostasis. When in a phosphorylated form, IGFBP-1 se-
questers IGFs with a high affinity, thereby inhibiting their 
actions. The production of IGFBP-1 is suppressed through 
insulin, which binds to insulin-response elements in the 
IGFBP-1 promoter region. So, reduced serum IGFBP-1 
levels reflect high insulin levels [57].
IGFBP-1 levels in both the placenta and cord blood of 
SGA neonates tend to be elevated when compared with 
those in AGA neonates [13, 32]. Corresponding to these 
changes, reduced CpG methylation of the promoter re-
gions of placental IGFBP-1 in the SGA neonates was 
found. These findings may provide an explanation of the 
observed lower level of bioactive IGF in cord blood of 
SGA neonates, as determined by an IGF-I-specific kinase 
receptor activation assay [32].
Short children born SGA show increased serum insu-
lin levels suggesting increased insulin secretion in re-
sponse to peripheral insulin resistance [58–60]. In a large 
cohort of short SGA children and adolescents, IGFBP-1 
levels significantly decreased with age and were compa-
rable to those encountered in normal statured subjects. 
This may reflect a normal metabolic state despite report-
ed higher insulin secretion [57]. In the same study, it was 
found that the –575 G/A single-nucleotide polymor-
phism (SNP) in the promotor region of the IGFBP-1 gene 
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significantly affected serum IGFBP-1 levels. The levels 
were lowest in children carrying the more common GG 
genotype. The –575 G/A SNP also significantly influ-
enced the relation between serum insulin and IGFBP-1 
levels. SGA children with comparable insulin secretion 
and carrying the GG genotype had significantly lower se-
rum IGFBP-1 levels (SDS) compared with SGA children 
carrying the AA genotype. The –575 G/A SNP is situated 
near at least 2 insulin response elements and could thus 
influence the modulation of insulin-dependent gene re-
pression [57].
IGF Binding Protein-2
IGFBP-2 plays an important role in metabolic signal-
ing, inflammation, and conditions such as obesity and 
diabetes [61, 62]. IGFBP-2 is widely expressed during fe-
tal development but postnatally it becomes predominant-
ly expressed in the liver. Although an insulin-regulated 
element has been identified within the IGFBP-2 gene pro-
moter, insulin inhibition of IGFBP-2 synthesis in vitro is 
far less rapid than the response of IGFBP-1 [63]. In con-
trast to IGFBP-1, serum concentrations of IGFBP-2 do 
not vary in response to meals or glucose infusions, but 
levels do increase after a prolonged period of fasting [64]. 
This indicates that the concentration of IGFBP-2 in the 
circulation merely reflects long-term alterations in hepat-
ic exposure to insulin, whereas that of IGFBP-1 mirrors 
short-term fluctuations in insulin levels. It has been sug-
gested that IGFBP-2 alters the activity of intracellular ki-
nases that modulate insulin signaling in metabolically ac-
tive tissues by both IGF-dependent and IGF-independent 
mechanisms, thereby modulating insulin sensitivity [65].
IGFBP-2 has not been extensively studied in SGA sub-
jects. One study found that in the placenta of SGA neo-
nates, the mRNA and protein levels of IGFBP-2 are high-
er compared to AGA neonates [13]. This was associated 
with a lower degree of CpG methylation of the promoter 
region of the IGFBP-2 gene in SGA neonates. A study in 
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bound fraction in the circulation of healthy 
subjects. Stable ternary 150 kD complexes 
are formed by an IGF, IGFBP-3 (to a lesser 
extent also with IGFBP-5) and ALS. In ad-
dition, there are binary 40–50 kD complex-
es consisting of an IGF and an IGFBP with 
a relatively shorter half-life in the circula-
tion. Only a very small fraction of the IGFs 
are present in the free unbound form. IGFs 
are released from the complexes by various 
types of IGFBP proteases (...) which in-
clude the (MMPs) PAPP-A2 and A. These 
proteases cleave IGFBP-3 and-5 (PAPP-
A2) and IGFBP-2, -4, and -5 (PAPP-A) and 
are thought to play an important role in 
IGFBP proteolysis. STCs inhibit the pro-
teolytic activities of PAPP-A and PAPP-
A2, thereby resulting in decreased levels of 
free IGF-1 and, consequently, decreased 
IGF-1 signaling. MMP, matrix metallopro-
teinases; IGF, insulin-like growth factor; 
IGFBP, IGF-binding proteins; PAPP, preg-
nancy-associated plasma protein.
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147 short SGA children showed that serum IGFBP-2 lev-
els were similar compared to their normal statured peers, 
and did not correlate with any metabolic or cardiovascu-
lar risk factors [66].
IGF Binding Protein-3
IGFBP-3 is the main circulating carrier of IGFs in 
postnatal life [67, 68]. In healthy subjects, the serum con-
centration of IGFBP-3 exceeds that of the other 5 binding 
proteins, and its affinity for IGF-I is higher than that of 
other binding proteins together [68, 69]. IGFBP-3 can 
modulate the effects of IGF-I by controlling the amount 
of free IGF-I. It can suppress its transfer from the circula-
tion to the tissues, and it can regulate the interaction be-
tween IGF-I and its receptor. IGFBP-3 also has a number 
of IGF-independent actions, which include inhibition of 
cell growth and induction of apoptosis [68, 70, 71].
Since mutations and deletions in the genes involved in 
the GH-IGF-axis are uncommon in short SGA children, 
studies have focused on factors that might alter gene ex-
pression. Regulation of IGFBP-3 gene expression is very 
complex, because expression can be induced both by fac-
tors that stimulate growth (e.g., GH and insulin) and by 
agents that inhibit growth such as the tumor suppressor 
p53 (TP53). The TP53 gene encodes at least 15 protein 
isoforms that bind to DNA and regulate gene expression 
to prevent mutations of the genome. The IGFBP3 gene is 
a direct target of TP53, actively participating in apoptotic 
pathways triggered by TP53 [68]. Marzano et al. [70] re-
ported that a member of the TP53 transcription factor 
family, namely, TP73, promotes IGFBP3 gene expression 
in actively proliferating cells. They also found that mRNA 
expression levels of TP73 and IGFBP3 in white blood cells 
are significantly lower in SGA children compared with 
healthy controls. The authors suggest that TP73 might be 
a good biomarker for assessing the risk for SGA children 
remaining short in adulthood.
In short SGA children, not only IGF-I but particularly 
IGFBP-3 levels are low (approximately –1.5 SDS) [9, 10, 
37]. Low IGFBP-3 levels are very uncommon in other 
short statured children (except GH deficiency). These low 
levels could be caused by a reduction in spontaneous GH 
production, since IGFBP-3 is stabilized in serum by form-
ing complexes with IGF-I and ALS, which are both 
 GH-dependent. There are also polymorphisms in the 
IGFBP3 promoter region that have been found to corre-
late with IGFBP-3 levels in short SGA children [72, 73]. 
The –202 A/C SNP is located near elements involved in 
directing IGFBP3 promotor activity and expression and 
is important in regulating IGFBP-3 levels [74]. Van der 
Kaay et al. [72] investigated the –202 A/C SNP and found 
that IGFBP-3 levels were highest in short SGA children 
carrying the AA genotype and significantly lower in chil-
dren carrying the AC and CC genotype.
Acid-Labile Subunit
Another key player in IGF biology is the ALS. The ami-
no acid sequence or structure is not related to other com-
ponents of the GH-IGF system. The ALS protein is orga-
nized into 3 domains: an N-terminal domain, a central 
domain containing 20 leucine-rich repeats, and 1 C-ter-
minal domain [75–77]. David et al. [78] described a 
horseshoe-shaped model showing positively charged re-
gions on the outer surface and a predominance of nega-
tively charged regions on the inner concave surface. This 
may facilitate the interaction with the C-terminal region 
of IGFBP3, which is positively charged. The production 
of ALS is mostly regulated by GH, the most potent in-
ducer of ALS mRNA in the liver [79]. The main and best-
known function of ALS is extending the half-life of IGF-I 
in the circulation by preventing glomerular filtration and 
proteolytic degradation [42].
Recently, serum ALS levels were investigated in a co-
hort of 312 short children born SGA [80]. Given the gen-
erally reduced IGF-I and IGFBP-3 levels in the SGA pop-
ulation, it was expected that mean ALS levels would also 
be reduced. It was shown that short SGA children tend to 
have lower ALS levels (–0.5 SDS) compared to healthy 
controls of similar age, albeit less reduced than IGF-I and 
IGFBP-3 levels (<–1 SDS). It might be that the spontane-
ous GH secretion in short SGA children is not reduced to 
such an extent that the production of ALS is seriously af-
fected, but there might also be other unknown factors in-
volved in the secretion of ALS.
The first patient with an IGFALS gene mutation was 
reported in 2004 by Domené et al. [81], who described a 
17-year-old boy with short stature, markedly reduced 
IGF-I and IGFBP-3 levels, and undetectable ALS levels. 
Since then several IGFALS gene mutations have been de-
scribed. Patients with a homozygous IGFALS deletion or 
duplication have a more severe phenotype compared to 
patients with a compound heterozygous IGFALS muta-
tion [81–85]. In general, children with an IGFALS muta-
tion show only mild to moderate short stature, despite se-
verely reduced serum IGF-I, IGFBP-3 levels, and ALS lev-
els [86, 87]. Subjects who are heterozygous carriers for a 
mutation in the IGFALS gene show approximately 1 SDS 
height loss when compared with wild-type individuals 
[88]. It has been suggested, that heterozygosity for IGFALS 
mutations may contribute to idiopathic short stature [89].
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Ternary Complex Formation
One aspect of the GH-axis that has received relatively 
little attention is complex formation between IGFs, 
IGFBP-3 and ALS. In addition, to a minor extent, IGFBP-5 
can also form a ternary complex with ALS and IGFs [90]. 
The formation of this ternary complex is very specific, 
since ALS has no affinity for free IGF-I, free IGF-II, free 
IGFBP-3 or free IGFBP-5 alone. This means that IGF-I 
(or IGF-II) must first bind to IGFBP-3 to which ALS then 
associates [90–92]. To efficiently form ternary complex-
es, there has to be a two- to threefold excess of ALS rela-
tive to IGF-I and IGFBP-3 [92]. The different molecular 
size classes of circulating IGF-IGFBP complexes can be 
determined using column chromatography after pre-in-
cubation of 125I-IGF-I with serum (Fig.  3) [47]. This 
method can be used as a functional test in assessing 
 IGF-IGFBP complex formation, for example, in patients 
with an IGFALS gene deletion or mutation [82].
Recently, we published normative data on the distri-
bution of 125I-IGF-I ternary (150 kD) and 125I-IGF-I bi-
nary 40–50 kD complexes for healthy normal statured 
children, adolescents and young adults [47]. In the circu-
lation of both young healthy boys and girls relatively less 
125I-IGF-I is sequestered into ternary complexes, but this 
increases significantly with age. This age dependency 
might be partially explained by the age-related and puber-
ty-related increase in IGFs, IGFBP-3, and ALS levels and 
decrease in IGFBP-1 levels.
Little is known about ternary complex formation in 
short children born SGA. In a cohort of 40 short SGA 
children 125I-IGF-I complex formation was studied. It 
appeared that short SGA children showed a lower 125I-
IGF-I-150 kD complex to 125I-IGF-I-40–50 kD ratio 
compared to age matched healthy controls [47]. This 
may have been the result of higher IGF-II levels (1.4 vs. 
0.1 SDS) and IGFBP-1 levels (0.6 vs. –0.2 SDS) in the 
short SGA children compared to the healthy controls. 
In the same study, height SDS in short SGA children 
was positively correlated with the amount of 125I-IGF-I 
trapped in the 150 kD complex. Interestingly, children 
with a height below or equal to the –3 SDS showed low-
er 150 kD complex formation compared with short 
SGA children with a height between the –3 and –2 SDS 
[47].
125I-IGF-I column chromatography is an ex vivo 
method of assessing ternary complex formation. To fur-
ther investigate the reduced ternary complex formation 
in young healthy children, we determined whether en-
dogenous IGF-I was indeed less present in the 150 kD 
ternary complex, by performing neutral chromatogra-
phy, without addition of 125I-IGF-I. This showed that 
most of the IGF-I was still present in the 150 kD ternary 
complex, even in those with severely reduced 125I-IGF-I 
ternary complex formation. Subsequent investigations 
showed that young healthy children had higher levels of 
proteolysed IGFBP-3 (29 kD), which cannot bind 125I-
IGF-I and thus results in reduced 125I-IGF-I 150 kD com-
plex formation. This is a similar phenomenon as previ-
ously described in the serum of pregnant women [93]. In 
addition, our data showed that young healthy children 
had considerable IGFBP-3 proteolytic activity, which de-
clined with age. Since proteolysed IGFBP-3 appears to 
bind unlabeled, endogenous IGF-I with a lower affinity 
than intact IGFBP-3, it is hypothesized that IGF-I can be 
released more easily from 29 kD IGFBP-3 enriched 150 
kD complexes [94]. The correlation between height SDS 
and 125I-IGF-I-150 kD complex formation in short SGA 
children presumably reflects a complicated relationship 
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Fig. 3. Representative examples of the distribution of radioactivity 
among the various molecular weight size classes after (125I)-hIGF-
I column chromatography of pooled normal serum (a) and a sub-
ject with severely reduced ternary complex formation (b). CPM, 
counts per minute; kD, kilo Dalton.
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between GH, IGF-I, IGFBP-3, ALS, and also IGFBP-3 
proteolysis [47]. Which protease(s) are involved here re-
mains to be elucidated.
IGFBP-3 Proteolysis
For IGF-I to exert its biological effects it must be re-
leased from its binding proteins. One important mecha-
nism for this is proteolysis of IGFBPs. Three classes of 
IGFBP proteases have been recognized. These include kal-
likreins, cathepsins, and matrix metalloproteinases [95]. 
They have been shown to cleave IGFBP-2 to -6 with vary-
ing specificity. Using protein sequencing and specific pro-
tease inhibitors, several proteases have been identified that 
are capable of cleaving specifically IGFBP-3, such as the 
kalikrein-like prostate-specific antigen and matrix metal-
loproteinases pregnancy-associated plasma protein-A2 
(PAPP-A2) [45, 95, 96]. Proteases are capable of cleaving 
42–40 kD IGFBP-3 into 29 kD and smaller fragments, as 
revealed after SDS gel electrophoresis, which have a sig-
nificantly reduced affinity for IGF-I, resulting in destabi-
lisation of the ternary complex and an increased bioavail-
ability of IGF-I to target tissues [94, 96, 97]. Another re-
lated metalloproteinase, PAPP-A, specifically cleaves 
IGFBP-2, IGFBP-4, and IGFBP-5 and is now known to be 
widely expressed in multiple tissues [96]. Stanniocalcins 
(STCs), widely expressed proteins involved in calcium and 
phosphate metabolism, have been shown to inhibit the ac-
tivities of these metalloproteinases. STC1 inhibits mainly 
PAPP-A, whereas STC2 affects PAPP-A2 [98, 99]. The 
physiological roles of the STCs in the IGF system and pos-
sibly SGA warrant further investigations.
IGFBP-3 proteolysis was first described in pregnant 
women, in whom almost all circulating IGFBP-3 is pro-
teolysed, particularly in the third trimester [93, 100, 101]. 
Since then, proteolytic fragments of IGFBP-3 have been 
detected in sera of newborns, children with IUGR, acute 
illness, and GH-deficient patients [102–104]. Cianfarani 
et al. [104] determined IGFBP-3 circulating molecular 
forms in approximately 70 patients with GH deficiency 
and 60 subjects with idiopathic short stature. Their re-
sults showed that patients with GH deficiency have in-
creased IGFBP-3 proteolytic activity, which was absent 
in all children with idiopathic short stature. Although 
spontaneous GH secretion is reduced in short SGA chil-
dren, none of the short SGA children investigated by us 
could be classified as GH deficient [9, 10]. Nonetheless, 
it was shown that they also have a higher level of proteo-
lysed 29 kD IGFBP-3 in their serum compared with 
healthy controls (35.1 vs. 12.2%), indicating a higher 
IGFBP-3 proteolytic activity [47]. This has led to the sug-
gestion that increased IGFBP-3 proteolytic activity in 
short SGA children merely represents a mechanism that 
attempts to compensate for the lower biological activity 
of IGF-I that nevertheless fails to induce adequate catch-
up growth [103]. This is supported by the recent finding 
that in healthy normal statured children, IGFBP-3 pro-
teolytic activity only appears to be increased during the 
first years of life [45, 100]. During these first years growth 
velocity is the highest, although IGF-I levels are relative-
ly low. To ensure bioavailability of IGF-I to target tissues, 
IGFBP-3 proteolytic activity must be increased. Thus, in 
conditions were IGF-I levels are (relatively) low, a prote-
ase system is active, resulting in proteolysis of IGFBP-3, 
which enhances the release of IGF-I from the ternary 
complex.
Until recently, there were no mutations described in 
genes encoding proteases that are capable of cleaving 
IGFBPs. However, Dauber et al. [105] described 5 chil-
dren of 2 unrelated families, 2 of whom were born 
SGA, with progressive growth failure, moderate micro-
cephaly and thin long bones due to loss of function 
mutation in the PAPPA2 gene. Whole-exome sequenc-
ing identified 2 different homozygous variants in the 
PAPPA2 gene. Functional studies showed loss of PAPP-
A2 function resulting in high circulating serum levels 
of total IGF-I, IGFBP-3, IGFBP-5, and ALS. Size-exclu-
sion chromatography showed a significant increase in 
ternary complex formation. However, the increase in 
IGF-I was not accompanied by an elevated IGF bioac-
tivity (i.e., the ability of IGF-I to phosphorylate the 
IGF-receptor). Free and bioactive IGF-I levels were low 
or in the low-normal range with a marked decrease in 
the bioactive/IGF-I ratio. It was suggested that this rel-
ative decrease in IGF bioactivity was due to an inabil-
ity of the abnormal PAPP-A2 to release IGF-I from its 
binding proteins by proteolysis. Apparently, PAPP-A2 
deficiency plays a role in stagnating growth in a sub-
population of short SGA patients that differs from the 
cohorts studied by us. Interestingly, treatment of 2 
PAPP-A2 deficient siblings with rIGF-I for 1 year 
 resulted in a clear increase in growth velocity (2.1 and 
3.1 SDS) and height SDS (0.4 SDS in both children) 
[106].
GH Treatment and Effect of Treatment 
Recombinant GH has been used since 1986 and has 
replaced GH extracted from human pituitaries. The indi-
cations for GH treatment have gradually extended from 
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replacement therapy in children with GH deficiency to 
conditions in which short stature is not due to GH defi-
ciency, including short stature in children born SGA. 
Various high-quality clinical trials on the effects of GH 
treatment have shown that most short children born SGA 
show catch-up growth during GH treatment with an sig-
nificant improvement in adult height expressed as SDS 
[107–111]. Since 2003, GH treatment for short children 
born SGA has been registered in Europe, the United 
States, and Japan.
Children born SGA comprise a heterogeneous group 
with a broad spectrum of clinical characteristics, and 
before starting GH treatment a thorough endocrine 
evaluation of a short infant presenting with SGA is nec-
essary to exclude hypothyroidism, celiac disease, mal-
nutrition, renal failure or chronic inflammation. Espe-
cially the latter condition has been associated with ab-
normalities in the GH/IGF-I axis, including GH/IGF-I 
insufficiency, GH/IGF-I resistance, down regulation of 
GH/IGF-I receptors, disruption in downstream GH/
IGF-I signaling pathways and dysregulation of IGFBPs 
[112, 113]. Interactions between proinflammatory cyto-
kines, such as interleukin 6, and the IGF system seem 
to be important factors for the onset of these abnor-
malities. In fact, it has been proposed that IUGR shares 
features with conditions characterized by chronic in-
flammation [112, 114].
Although GH therapy is effective in increasing adult 
height in short SGA children, the variability in catch-up 
growth is high [107]. Because of rising healthcare costs, it 
is becoming increasingly important to identify short chil-
dren who will benefit from long-term GH treatment. It 
has been shown that, among others, young age at start of 
treatment, GH dose and IGFBP-3 levels are important 
determinants of GH treatment response [115–117]. How-
ever, even after accounting for these variables, there re-
mains a wide variation, which is difficult to explain. Ani-
mal data suggest that the presence of sufficient ALS in 
serum is required for maximal effectiveness of exogenous 
GH [118]. Also, it has been shown that serum ALS levels 
at start of GH treatment are positively correlated with 
height SDS at start of puberty [80]. De Ridder et al. [116] 
described a prediction model for height SDS at onset of 
puberty. Adding ALS to this prediction model resulted in 
a moderate improvement (5%) in accuracy. As with all 
variables, the contribution of ALS to the prediction mod-
el was modest. However, it suggests that determining se-
rum ALS at start of GH treatment may contribute to a 
slightly more accurate prediction of the growth response 
to GH treatment.
Whether GH treatment affects IGFBP-3 proteolysis is 
not clear since contradictory results have been reported 
[119–121]. IGFBP-3 proteolytic activity was assessed in 
sera of short SGA children after 1 year of GH treatment 
[47]. This study showed no increased IGFBP-3 proteoly-
sis, while, 125I-IGF-I ternary complex formation, serum 
IGF-I levels, and growth velocity increased significantly. 
These findings suggest that GH treatment induces suffi-
ciently high serum IGF-I levels to stimulate growth. Con-
versely, it has been shown that during GH treatment, IGF-
I levels above the 1 SDS are not unusual in short children 
born SGA [37, 122]. These high IGF-I levels are a concern 
and often subject of debate because of the unknown long-
term consequences [123]. It has been suggested that IGF-
bioactivity is a more sensitive method for monitoring the 
effects of GH treatment than immunoreactive serum IGF-
I levels. In children with Prader-Willi syndrome, Bakker 
et al. [124] showed that despite high, GH-induced, immu-
noreactive serum IGF-I levels, there was no difference in 
IGF-bioactivity compared to untreated healthy controls, 
which is reassuring. There are, however, no data on IGF-
bioactivity in short SGA children treated with GH.
Conclusions
As the GH-IGF axis is involved in many physiological 
processes, understanding its molecular and (epi) genetic 
regulation is fundamental in optimizing our knowledge of 
the aetiology of the SGA phenotype. The most notable ab-
normalities of the IGF system in SGA neonates are the low-
ered levels of IGF-I in both cord blood and the placenta of 
SGA neonates. In contrast, the expression of the IGF-I in-
hibiting IGFBP-1 and IGFBP-2 in the placenta of SGA ne-
onates is increased compared to AGA neonates. These ob-
servations suggest a decreased bioactivity of IGF-I in utero 
in SGA neonates. IGF-I levels remain reduced in SGA chil-
dren with short stature, as well as those of IGFBP-3 and 
ALS. IGFBP-3 in the circulation of short SGA children ap-
pears to be subject to proteolysis to a higher degree than 
normal. Proteolyzed IGFBP-3 can, just like IGFBP-3, form 
ternary complexes with ALS and IGFs. However, it is as-
sumed that the IGFs are bound in these complexes with a 
lower affinity and thus may be released easier. The bio-
logical significance of this remains uncertain but may in-
dicate a compensatory mechanism for the lower IGF-I lev-
els in short SGA children to enhance IGF-I bioavailability. 
However, in contrast, in 2 short SGA children an inactivat-
ing mutation in one of the IGFBP-3 proteases, PAPPA-2, 
has been found, leading to enhanced levels of IGF-I, 
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IGFBP-3, and ALS. It is not clear whether this concerns 2 
exceptional cases of SGA. Further studying of IGFBP-3 
proteolysis and the determination of the IGF bioactivity in 
serum of short SGA children is needed [125].
The lack of a clear identifiable cause of short stature in 
most SGA children renders an etiopathological approach 
to therapy difficult. Increasing our knowledge of the vari-
ability of the SGA phenotype is not only important for 
diagnosis but also for treatment options and expectations 
regarding the growth response. Pharmacogenetic studies 
might clarify some of the wide variation in growth re-
sponse. Also, there is a necessity to optimize the GH dos-
age, since this will help to improve growth results. By us-
ing advanced growth prediction models, it might become 
feasible to decide on an individual GH dosage from start 
of treatment, thereby aiming for the best treatment op-
tions for each individual child. Further research is needed 
and clinical and basic researchers must continue working 
closely together to achieve advancements in this field.
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